An Open label, Safety Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia
Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia with open-label Part I and randomized, double-blind, placebo-controlled Part II.
Single-arm, open-label dose titration phase 2 clinical trial of (+)-α-DHTBZ for the treatment of tardive dyskinesia (TD)
100 Clinical Results associated with Adeptio Pharmaceuticals Ltd.
0 Patents (Medical) associated with Adeptio Pharmaceuticals Ltd.
100 Deals associated with Adeptio Pharmaceuticals Ltd.
100 Translational Medicine associated with Adeptio Pharmaceuticals Ltd.